Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several safety/adverse reaction and indication/dosing statements are supported by the provided label excerpts, but multiple claims are unsupported or conflict with the label excerpts provided (notably mechanism of action and armodafinil/modafinil statements). Several additional claims (e.g., exclusivity/generics/pricing/manufacturers/brand origin) are not addressed in the FDA prescribing information and therefore cannot be confirmed.
Category Scores
Accurate Statements
Nuvigil is prescribed to improve wakefulness in adults with narcolepsy.
Section 1: indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy.
Nuvigil is prescribed to improve wakefulness in adults with obstructive sleep apnea as an adjunct to primary sleep apnea treatment.
Section 1: NUVIGIL indicated for excessive sleepiness associated with OSA; not as treatment for the underlying obstruction; CPAP maximal effort prior to initiating NUVIGIL.
Nuvigil is prescribed to improve wakefulness in adults with shift work sleep disorder.
Section 1: indicated to improve wakefulness in adult patients with excessive sleepiness associated with shift work disorder (SWD).
Common side effects of Nuvigil can include headache.
Section 6.1: most common adverse reactions (≥5%) more frequent than placebo include headache.
Common side effects of Nuvigil can include nausea.
Section 6.1: most common adverse reactions include nausea.
Common side effects of Nuvigil can include dizziness.
Section 6.1: most common adverse reactions include dizziness.
Common side effects of Nuvigil can include trouble sleeping.
Section 6.1: insomnia is a most common adverse reaction.
More serious, though less common, side effects of Nuvigil can occur.
Section 6.1 includes discussion of additional (dose-related) adverse reactions and that there are other adverse reactions beyond the most common.
Dosage for Nuvigil is determined by a healthcare professional based on the specific medical condition and the individual patient's response.
Section 2: dosing recommendations by indication (OSA/narcolepsy vs SWD); label implies individualized prescribing within recommended ranges.
Nuvigil 150 mg is one of the available formulations.
Provided label excerpts do not explicitly confirm formulations, but the dosing excerpt references 150 mg as a recommended dose in OSA/narcolepsy and SWD.
Unsupported Statements
Nuvigil 150 mg price information is not available in the provided text.
Not a claim about prescribing information; label excerpts provided do not contain pricing.
Patent exclusivity for Nuvigil (armodafinil) has already expired in many regions.
Not addressed in the provided FDA prescribing information excerpts.
Generic versions of armodafinil, the active ingredient in Nuvigil, have become available following expiry of patent protections.
Not addressed in the provided FDA prescribing information excerpts.
Generic alternatives to Nuvigil often offer a more affordable option compared to the brand-name drug.
Not addressed in the provided FDA prescribing information excerpts.
Nuvigil was originally developed and marketed by Cephalon, Inc. (now part of Teva Pharmaceutical Industries).
Not addressed in the provided FDA prescribing information excerpts.
Generic versions of armodafinil are manufactured by various pharmaceutical companies that have received regulatory approval to produce them.
Not addressed in the provided FDA prescribing information excerpts.
Nuvigil was originally developed and marketed by Cephalon, Inc. (now part of Teva Pharmaceutical Industries).
Not addressed in the provided FDA prescribing information excerpts.
Nuvigil is a wakefulness-promoting agent that contains armodafinil.
Label excerpts support that NUVIGIL contains armodafinil, but the excerpted sections provided do not explicitly call it a 'wakefulness-promoting agent.'
Nuvigil is believed to work by affecting neurotransmitters in the brain involved in regulating the sleep-wake cycle.
Section 12.1 states mechanism(s) through which armodafinil promotes wakefulness is unknown; does not support 'affecting neurotransmitters' explanation.
Nuvigil contains armodafinil.
The provided excerpt header indicates armodafinil as active ingredient, but the specific statement 'contains armodafinil' is not explicitly quoted in the excerpted label text.
Armodafinil is an enantiomer of modafinil.
Not supported or contradicted by provided label excerpts.
Modafinil is the active ingredient in Provigil.
Not addressed in the provided FDA prescribing information excerpts for NUVIGIL.
Armodafinil is a longer-acting form of modafinil.
Not addressed in provided label excerpts.
Armodafinil potentially offers more sustained wakefulness.
Not addressed in provided label excerpts.
Common side effects of Nuvigil can include nervousness.
Label excerpt 6.1 lists most common adverse reactions as headache, nausea, dizziness, and insomnia; anxiety/nervousness appear in the warnings/precautions context but 'nervousness' as a common side effect is not explicitly supported as ≥5%.
Common side effects of Nuvigil can include anxiety.
Anxiety is referenced in Section 5.5 as a reason for discontinuation more often in trials; not explicitly listed as a common (≥5%) adverse reaction in Section 6.1 excerpts.
Common side effects of Nuvigil can include nervousness and anxiety as 'common side effects.'
Supported as psychiatric symptoms leading to discontinuation (Section 5.5), but not explicitly supported as 'common side effects' in the provided adverse reaction excerpt.
Common side effects of Nuvigil can include diarrhea.
Diarrhea is not listed among the most common adverse reactions (≥5%) in Section 6.1 excerpts.
Contradictions
Low
AI Statement
Nuvigil is believed to work by affecting neurotransmitters in the brain involved in regulating the sleep-wake cycle.
Label Reference
Section 12.1: 'The mechanism(s) through which armodafinil promotes wakefulness is unknown.'
Important Omissions
For OSA, NUVIGIL is indicated to treat excessive sleepiness and not the underlying obstruction, and patients should make a maximal effort to treat with CPAP for an adequate period prior to initiating NUVIGIL.
Importance:
Moderate
Dose specifics from the label (e.g., OSA/narcolepsy: 150 mg to 250 mg once daily in the morning; SWD: 150 mg once daily approximately 1 hour prior to shift) were not provided explicitly for each claim.
Importance:
Moderate
Contraindication (hypersensitivity to modafinil or armodafinil) was not stated in the AI-generated list.
Importance:
Moderate
Key warnings related to persistent sleepiness and reassessment/avoiding dangerous activities were not explicitly stated.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some safety-relevant statements (e.g., mechanism explanation) conflict with the label excerpt that mechanism is unknown, and several psychiatric and adverse reaction claims are imprecisely labeled as 'common side effects' without support in the adverse reaction excerpt. Missing explicit contraindication and persistent sleepiness warning details from the provided label excerpts increases incompleteness.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Unsupported/incorrect mechanistic explanation and several imprecise 'common side effect' claims not supported by the provided adverse reaction excerpt.
Suggested Improvement
Limit side effect claims to those explicitly supported (headache, nausea, dizziness, insomnia as ≥5% common adverse reactions in the provided excerpt), and remove or qualify statements about mechanism that conflict with 'mechanism is unknown.' Include label-excerpt details for contraindications and key warnings (persistent sleepiness/reassessment and OSA CPAP limitation) when describing safety.